ABSTRACT
Administration of targeted immunosuppression, in the form of genetically engineered antibodies, is commonplace in solid organ transplantation. Polyclonal antibodies, such as rabbit anti-thymocyte globulin, offer global immunosuppression by targeting several cell surface antigens on B-and Tlymphocytes. However, secondary to their broad therapeutic targets, they are associated with infection, infusion related reactions, inter-batch variability, and post-transplant malignancy. Nevertheless, polyclonal antibodies are still commonly administered for induction and treatment of allograft rejection and offer an important role in current solid organ transplantation, which is beyond the scope of this chapter.
